Safety and efficacy of adding voclosporin to standard treatment of lupus nephritis in adult patients: a meta-analysis and time-to-event analysis of randomized controlled trials.
Mohamed Saad Sayed, Mohamed R Murad, Hasan Naeem Kareem et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis and time-to-event analysis pooled three randomized controlled trials comparing voclosporin plus standard treatment with placebo plus standard treatment in 770 adults with lupus nephritis. Voclosporin was associated with faster achievement of urine protein-to-creatinine ratio (UPCR) thresholds: below 50% of baseline (HR 1.97, 95% CI 1.66 to 2.35) and below 0.5 g/g (HR 1.84, 95% CI 1.43 to 2.37). Response rates were also higher at reported follow-up points, but overall adverse events and treatment-related serious adverse events increased.
Key findings
- UPCR fell below 50% of baseline more rapidly with voclosporin (HR: 1.97, 95% CI 1.66 to 2.35, log-rank p < 0.001).
- Achievement of UPCR below 0.5 g/g was more rapid with voclosporin (HR: 1.84, 95% CI 1.43 to 2.37, log-rank p < 0.001).
- Complete and partial response rates were higher in the voclosporin group at 6 months and 12 months, respectively.
- Overall adverse events and treatment-related serious adverse events significantly increased with voclosporin.
Why it matters
The findings indicate that adding voclosporin may improve proteinuria and response outcomes in lupus nephritis, while also increasing adverse-event concerns. This balance is clinically important when considering evidence for an add-on treatment: efficacy signals should be interpreted alongside safety, and the pooled results do not establish that benefits outweigh harms for every patient.
What to keep in mind
The analysis included only three randomized trials; the authors state that larger primary studies are needed to clarify voclosporin’s safety profile.